Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ELN's Cash to Debt is ranked higher than
92% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ELN: No Debt )
ELN' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: No Debt

Equity to Asset 0.94
ELN's Equity to Asset is ranked higher than
96% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ELN: 0.94 )
ELN' s 10-Year Equity to Asset Range
Min: -0.31   Max: 0.94
Current: 0.94

-0.31
0.94
F-Score: 6
Z-Score: 35.83
M-Score: 99999999.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -188750.00
ELN's Operating margin (%) is ranked lower than
54% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ELN: -188750.00 )
ELN' s 10-Year Operating margin (%) Range
Min: -188750   Max: 36.49
Current: -188750

-188750
36.49
Net-margin (%) -68700.00
ELN's Net-margin (%) is ranked lower than
54% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ELN: -68700.00 )
ELN' s 10-Year Net-margin (%) Range
Min: -68700   Max: 14012.5
Current: -68700

-68700
14012.5
ROE (%) -22.23
ELN's ROE (%) is ranked higher than
70% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. ELN: -22.23 )
ELN' s 10-Year ROE (%) Range
Min: -2269.82   Max: 69.91
Current: -22.23

-2269.82
69.91
ROA (%) -8.38
ELN's ROA (%) is ranked higher than
77% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ELN: -8.38 )
ELN' s 10-Year ROA (%) Range
Min: -76.63   Max: 31.96
Current: -8.38

-76.63
31.96
ROC (Joel Greenblatt) (%) -81.48
ELN's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. ELN: -81.48 )
ELN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -282.57   Max: 73.09
Current: -81.48

-282.57
73.09
Revenue Growth (%) -100.00
ELN's Revenue Growth (%) is ranked higher than
51% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. ELN: -100.00 )
ELN' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 34.1
Current: -100

-100
34.1
EPS Growth (%) -13.10
ELN's EPS Growth (%) is ranked higher than
74% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. ELN: -13.10 )
ELN' s 10-Year EPS Growth (%) Range
Min: -55.2   Max: 23.5
Current: -13.1

-55.2
23.5
» ELN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ELN Guru Trades in Q1 2013

Andreas Halvorsen 9,372,400 sh (New)
Jean-Marie Eveillard 2,323,819 sh (New)
Seth Klarman 9,126,227 sh (New)
Steven Cohen 401,918 sh (+1291.1%)
Vanguard Health Care Fund 19,470,300 sh (+90.24%)
Michael Price 1,100,000 sh (+22.22%)
Robert Bruce 165,900 sh (unchged)
George Soros Sold Out
Ray Dalio Sold Out
Jim Simons 161,500 sh (-89.77%)
» More
Q2 2013

ELN Guru Trades in Q2 2013

Mario Gabelli 55,800 sh (New)
Eric Mindich 3,604,184 sh (New)
Daniel Loeb 8,500,000 sh (New)
John Paulson 5,100,000 sh (New)
Jeremy Grantham 300,000 sh (New)
Steven Cohen 1,719,463 sh (+327.81%)
Jean-Marie Eveillard 2,739,100 sh (+17.87%)
Robert Bruce 165,900 sh (unchged)
Vanguard Health Care Fund 19,470,300 sh (unchged)
Paul Singer 2,569,634 sh (unchged)
Daniel Loeb 3,500,000 sh (unchged)
Stanley Druckenmiller Sold Out
Seth Klarman Sold Out
Jim Simons Sold Out
Michael Price 823,150 sh (-25.17%)
Andreas Halvorsen 4,661,400 sh (-50.26%)
» More
Q3 2013

ELN Guru Trades in Q3 2013

Louis Moore Bacon 424,117 sh (New)
Jim Simons 1,261,597 sh (New)
Jeremy Grantham 1,040,996 sh (+247%)
Mario Gabelli 149,600 sh (+168.1%)
Steven Cohen 3,159,074 sh (+83.72%)
Paul Singer 3,200,000 sh (+24.53%)
Daniel Loeb 10,000,000 sh (+17.65%)
Robert Bruce 165,900 sh (unchged)
Jean-Marie Eveillard 2,000 sh (unchged)
Vanguard Health Care Fund 19,470,300 sh (unchged)
Michael Price Sold Out
Andreas Halvorsen Sold Out
John Paulson Sold Out
Jean-Marie Eveillard 1,000,000 sh (-63.49%)
Eric Mindich 855,000 sh (-76.28%)
» More
Q4 2013

ELN Guru Trades in Q4 2013

Jeremy Grantham Sold Out
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Eric Mindich Sold Out
Daniel Loeb Sold Out
Vanguard Health Care Fund Sold Out
Mario Gabelli Sold Out
Jim Simons Sold Out
Jean-Marie Eveillard Sold Out
Robert Bruce Sold Out
Paul Singer Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ELN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Daniel Loeb 2013-12-31 Sold Out 3.9%$15.72 - $18.14 $ 18.166%0
Vanguard Health Care Fund 2013-12-31 Sold Out 1%$15.72 - $18.14 $ 18.166%0
Jean-Marie Eveillard 2013-12-31 Sold Out 0.05%$15.72 - $18.14 $ 18.166%0
Mario Gabelli 2013-12-31 Sold Out 0.01%$15.72 - $18.14 $ 18.166%0
Michael Price 2013-09-30 Sold Out 1.6%$13.98 - $15.79 $ 18.1620%0
Daniel Loeb 2013-09-30 Add 17.65%0.59%$13.98 - $15.79 $ 18.1620%10000000
John Paulson 2013-09-30 Sold Out 0.51%$13.98 - $15.79 $ 18.1620%0
Jean-Marie Eveillard 2013-09-30 Reduce -63.49%0.08%$13.98 - $15.79 $ 18.1620%1000000
Mario Gabelli 2013-09-30 Add 168.1%0.01%$13.98 - $15.79 $ 18.1620%149600
Seth Klarman 2013-06-30 Sold Out 3.5%$11.45 - $14.17 $ 18.1647%0
Daniel Loeb 2013-06-30 New Buy2.7%$11.45 - $14.17 $ 18.1647%8500000
John Paulson 2013-06-30 New Buy0.51%$11.45 - $14.17 $ 18.1647%5100000
Michael Price 2013-06-30 Reduce -25.17%0.43%$11.45 - $14.17 $ 18.1647%823150
Mario Gabelli 2013-06-30 New Buy0.01%$11.45 - $14.17 $ 18.1647%55800
Seth Klarman 2013-03-31 New Buy3.5%$9.4 - $12 $ 18.1667%9126227
Vanguard Health Care Fund 2013-03-31 Add 90.24%0.43%$9.4 - $12 $ 18.1667%19470300
Michael Price 2013-03-31 Add 22.22%0.31%$9.4 - $12 $ 18.1667%1100000
Ray Dalio 2013-03-31 Sold Out 0.11%$9.4 - $12 $ 18.1667%0
Jean-Marie Eveillard 2013-03-31 New Buy0.09%$9.4 - $12 $ 18.1667%2323819
George Soros 2013-03-31 Sold Out 0.05%$9.4 - $12 $ 18.1667%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Elan Corp PLC

Cutting Loose: Seth Klarman's Active Second Quarter Selling and Trimming
Seth Klarman, the legendary value investor and portfolio manager of The Baupost Group, was actively trimming and selling in the second quarter of 2013. His current portfolio shows 24 stocks, five of them new, and a total value of $4.02 billion. His quarter-over-quarter turnover is 22%. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 3.90
ELN's P/E(ttm) is ranked higher than
97% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. ELN: 3.90 )
ELN' s 10-Year P/E(ttm) Range
Min: 3.9   Max: 69.64
Current: 3.9

3.9
69.64
P/B 4.46
ELN's P/B is ranked higher than
61% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ELN: 4.46 )
ELN' s 10-Year P/B Range
Min: 1.85   Max: 1815.2
Current: 4.46

1.85
1815.2
PEG 0.10
ELN's PEG is ranked higher than
99% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ELN: 0.10 )
ELN' s 10-Year PEG Range
Min: 0   Max: 1.3
Current: 0.1

0
1.3
Shiller P/E 27.33
ELN's Shiller P/E is ranked higher than
77% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. ELN: 27.33 )
ELN' s 10-Year Shiller P/E Range
Min: 23.06   Max: 27.33
Current: 27.33

23.06
27.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.20
ELN's Price/Net Cash is ranked higher than
77% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ELN: 5.20 )
ELN' s 10-Year Price/Net Cash Range
Min: 4.11   Max: 59.69
Current: 5.2

4.11
59.69
Price/Net Current Asset Value 5.10
ELN's Price/Net Current Asset Value is ranked higher than
77% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. ELN: 5.10 )
ELN' s 10-Year Price/Net Current Asset Value Range
Min: 4.02   Max: 1107.55
Current: 5.1

4.02
1107.55
Price/Tangible Book 4.70
ELN's Price/Tangible Book is ranked higher than
66% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ELN: 4.70 )
ELN' s 10-Year Price/Tangible Book Range
Min: 3.7   Max: 57.06
Current: 4.7

3.7
57.06
Price/DCF (Projected) 69.80
ELN's Price/DCF (Projected) is ranked lower than
82% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. ELN: 69.80 )
ELN' s 10-Year Price/DCF (Projected) Range
Min: 0.35   Max: 64.27
Current: 69.8

0.35
64.27
Price/Graham Number 0.90
ELN's Price/Graham Number is ranked higher than
94% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. ELN: 0.90 )
ELN' s 10-Year Price/Graham Number Range
Min: 0.71   Max: 12.43
Current: 0.9

0.71
12.43
Earnings Yield (Greenblatt) 4.80
ELN's Earnings Yield (Greenblatt) is ranked higher than
62% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ELN: 4.80 )
ELN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 4.8
Current: 4.8

0.3
4.8
Forward Rate of Return (Yacktman) -2.00
ELN's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ELN: -2.00 )
ELN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.6   Max: -6.3
Current: -2

-18.6
-6.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EAN.Germany, DRX.Germany
Elan Corp PLC, an Irish public limited company, is a neuroscience-based biotechnology company. It was incorporated as a private limited company in Ireland in December 1969 and became a public limited company in January 1984. It is a neuroscience-based biotechnology company and its business is organized into two business units namely BioNeurology and Elan Drug Technologies (EDT). On September 16, 2011, it announced the completion of the merger between Alkermes, Inc. and EDT. In BioNeurology, the company is developing therapies for serious diseases that have long been considered intractable, including MS, Alzheimer's disease and Parkinson's disease. EDT develops and manufactures pharmaceutical products that deliver clinically meaningful benefits to patients, using its experience and proprietary drug technologies in collaboration with pharmaceutical companies. Tysabri, a treatment for relapsing forms of MS, competes mainly with Avonex, Betaseron(r), Berlex. The pharmaceutical industry is subject to significant regulation by international, national, state and local governmental regulatory agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide